RxDoctor Payments Data

Gene Levinstein, MD

Pain Medicine · Allentown, PANPI 1366494296

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $4,200 of the $6,812 with a category attached, or 61.7%. Kaleo, Inc. accounts for 83.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $5,765 and has fallen 96.4% since, to $206 in 2024.

$6,812in general payments, 2019–2025

Across 47 payments — averaging $144.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kaleo, Inc.$6K
  • Surgentec$456
  • Galderma Laboratories, L.p.$340
  • AbbVie$143
  • Scilex Pharmaceuticals Inc.$39
  • Biotronik NRO, Inc.$37
  • plus $130 from 6 others

What the payments were for

  • Speaking & faculty fees$4,20062%
  • Travel & lodging$1,81827%
  • Food & beverage$79412%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,812 in reported general payments places this provider in the 80th percentile of 294 pain medicine providers in Pennsylvania.

See all pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$132,659
Medicare patients
134
Services billed
896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl23$20,045
Lidocaine19$2,161
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen101$1,827
Oxycodone Hcl92$1,512
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen40$1,108
Morphine Sulfate ErMorphine Sulfate21$420
Pregabalin25$346
Tramadol Hcl33$253
Celecoxib16$241
Cyclobenzaprine Hcl62$215
Baclofen25$193
Gabapentin35$186
Tizanidine Hcl25$124
Meloxicam35$103
Amoxicillin27$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$36$20,04523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 294 pain medicine providers in Pennsylvania.

Other pain medicine in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →